US FDA’s Regulatory Affairs Office Building Case For More User Fee Funding
Executive Summary
ORA represented only a small fraction of the user fee programs’ costs in recent years, but wants to show its importance to the review process.
You may also be interested in...
Bending PDUFA’s Cost Curve: PhRMA Looking For Sustainable Program Growth
Industry feels that sufficient program management tools are in place, but a PDUFA VII negotiator says they need more time to mature.
US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.
Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says
Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.